TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04234048: Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Sponsor: SciTech Development, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 46 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,382,304

Rescue Site Savings

+$911,064

Unlock Full NCT04234048 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04234048 Rescue Dossier →